Intensity-Modulated Radiation Therapy for Lymph Node Metastases in Bladder Cancer

Author(s):  
M. Milosevic ◽  
M. Gospodarowicz ◽  
M. Jewett ◽  
R. Bristow ◽  
T. Haycocks
2005 ◽  
Vol 173 (4S) ◽  
pp. 359-359
Author(s):  
Marta Sanchez-Carbayo ◽  
Lee Richstone ◽  
Nicholas Socci ◽  
Wentian Li ◽  
Nille Behrendt ◽  
...  

2003 ◽  
Vol 2 (1) ◽  
pp. 165 ◽  
Author(s):  
A. Fleischmann ◽  
S. Madersbacher ◽  
G.N. Thalmann ◽  
R. Markwalder ◽  
U. Studer

2001 ◽  
Vol 125 (9) ◽  
pp. 1197-1199 ◽  
Author(s):  
Liang Cheng ◽  
David G. Bostwick ◽  
Guang Li ◽  
Shaobo Zhang ◽  
Alexander O. Vortmeyer ◽  
...  

Abstract Context.—Molecular analysis of microsatellite alterations of biologically distinct tumor cell subpopulations from the same patient may aid in the determination of tumor origin and further our understanding of the genetic basis of cancer progression. Design.—The authors examined the pattern of allelic loss with polymorphic microsatellite markers on chromosome 9p21 (D9S161, D9S171, IFNA), regions of putative tumor suppressor gene p16, and on chromosome 17p13 (TP53), the p53 locus, in matched primary and metastatic bladder cancers from 9 patients. All patients underwent cystectomy for bladder cancer and had regional lymph node metastases at the time of surgery. Genomic DNA was prepared from primary cancers and matched synchronous lymph node metastases using a microdissection method. Results.—The overall frequency of allelic loss was 78% in primary cancer and 89% in paired metastatic cancer. The frequency of allelic loss in the primary cancer was 86% with D9S161, 67% with D9S171, 71% with IFNA, and 80% with TP53. The frequency of allelic loss in matched metastatic cancer was 100% with D9S161, 62% with D9S171, 71% with IFNA, and 80% with TP53. An identical pattern of allelic imbalance (allelic loss or retention) at multiple DNA loci was observed in matched primary and metastatic carcinoma in 8 (88%) cases. One case showed allelic loss in the metastasis, but not in the primary cancer. Conclusions.—The pattern of allelic loss at chromosome 9p21 (p16) and 17p13 (p53) was generally maintained during cancer progression to metastasis, and identical allelic loss in primary cancer was conserved in paired metastatic carcinoma. These data suggest that these genetic changes may be useful in establishing a diagnosis and determining tumor origins in difficult cases.


Urology ◽  
2019 ◽  
Vol 131 ◽  
pp. 150-156 ◽  
Author(s):  
Kinnari R. Patel ◽  
Benjamin L. Taylor ◽  
Francesca Khani ◽  
Thomas J. Guzzo ◽  
Douglas S. Scherr ◽  
...  

2002 ◽  
Vol 167 (2 Part 1) ◽  
pp. 651-651
Author(s):  
R.D. Mills ◽  
W.H. Turner ◽  
A. Fleischmann ◽  
R. Markwalder ◽  
G.N. Thalmann ◽  
...  

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 15530-15530
Author(s):  
C. Wulfing ◽  
E. Herrmann ◽  
T. Kopke ◽  
E. Eltze ◽  
J. Neumann ◽  
...  

15530 Introduction: Vascular endothelial growth factors (VEGF) -C, -D and their receptor Flt-4 play an emerging role in lymphangiogenesis of different tumor types. Our aim was to determine the role of VEGF-C, VEGF-D and Flt-4 in invasive transitional cell carcinoma of the bladder. Material and Methods: Archival tumor tissue of 286 patients, who had previously undergone radical cystectomy at our institution, was reviewed and representative tumor blocks were selected for constructing a tissue microarray (TMA). Paraffin sections were assessed immunohistochemically using mono- and polyclonal antibodies against VEGF-C, VEGF-D and Flt-4. Staining results were analysed semiquantitatively and correlated with various clinicopathological factors. Results: Overexpression of VEGF-C, VEGF-D and Flt-4 was found in 24.1%, 37.4% and 46.3% of cases, respectively. While there was no association of VEGF-C to histopathological parameters and clinical outcome, patients with VEGF-D overexpression had higher pathological tumor stages (p=0.021) and regional lymph node metastases (p=0.016). Furthermore, they had significantly worse disease-free survival (p=0.042). Overexpression of Flt-4 was found in the subgroup of G3- and G4-tumors (p=0.001) and correlated with a shorter period of disease- free survival (p=0.033). Conclusion: VEGF-C, VEGF-D and Flt-4 are overexpressed in bladder cancer. VEGF-D predicts higher tumor stages and regional lymph node metastases. It is associated with a worse disease-free survival as well as Flt-4 in the subgroup of high-grade tumors. Further studies should be initiated to evaluate VEGF-D and Flt-4 as potential targets in bladder cancer. No significant financial relationships to disclose.


Sign in / Sign up

Export Citation Format

Share Document